We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ondine Biomedical Inc. | LSE:OBI | London | Ordinary Share | CA68234M2058 | COM SHS NPV (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -0.38% | 6.625 | 6.50 | 6.75 | 6.75 | 6.625 | 6.65 | 119,006 | 14:16:51 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 638k | -19.37M | -0.0996 | -0.66 | 12.88M |
From Apr 2023 to Apr 2024
TIDMOBI
RNS Number : 2523A
Ondine Biomedical Inc.
23 May 2023
23 May 2023
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
Annual Report for the Year Ended 31 December 2022
Ondine Biomedical (AIM: OBI) announces that its Annual Report for the year ended 31 December 2022 was posted on 23 May 2022 and is available on the Ondine website at: https://ondinebio.com/investors/reports-documentation/
Hot Features
Premium
Ondine Biomedical Inc.
+001 (1) 604 838
Angelika Vance, Corporate Communications 2702
Singer Capital Markets (Nominated Adviser
and Joint Broker)
+44 (0)20 7496
Aubrey Powell, Asha Chotai, Sam Butcher 3000
RBC Capital Markets (Joint Broker)
+44 (0) 20 7653
Rupert Walford, Kathryn Deegan 4000
Vane Percy & Roberts (Media Contact)
+44 (0) 77 1000
Simon Vane Percy, Amanda Bernard 5910
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave(TM). It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACSBLGDURDDDGXD
(END) Dow Jones Newswires
May 23, 2023 02:00 ET (06:00 GMT)
1 Year Ondine Biomedical Chart |
1 Month Ondine Biomedical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
